2021 IPO

Benson Hill Biosystems Stock

Agricultural biotechnology company focused on the development of traits to increase intrinsic crop yield

Sign up today and learn more about Benson Hill Biosystems Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Benson Hill Biosystems Stock

According to the company, boosting crop yields on existing acreage and with limited inputs is the foremost challenge in sustainable production agriculture. With the global population projected to reach nine billion by 2050, agricultural output must increase by 70% in this timeframe. As nations such as the United States pursue agriculture-intensive energy policies, demand and price volatility for agriculture commodities will continue to intensify. Diminishing agricultural resources such as arable land and fresh water will further compound this challenge. In the last twenty years, crop yields have improved from intensive breeding programs, increased planting densities, and biotech traits such as insect resistance and herbicide tolerance. However, blockbuster trait releases in recent years are only having single digit percentage impacts on yield. At a time when step changes are needed in crop productivity, yields are plateauing. One contributing factor to the decline in crop development is that nearly all commercial biotech traits are single-gene approaches to protecting yield. But to realize step changes and avoid a yield plateau, the company believes the industry must innovate beyond single-gene approaches to protecting yield, and realize step wise gains by increasing intrinsic yield. Benson Hill states that it is dedicated to delivering substantial production gains to the agriculture sector by advancing biotech-based traits to increase intrinsic yield.

Funding History

January 2013$300K
May 2013$250K
August 2013$451K
April 2014$30K
June 2014$1.3M
August 2014$50K
August 2015$7.3M
May 2017$25.0M
September 2018$60.0M


Founder, President & CEO

Matthew B. Crisp


Todd C. Mockler


Lee N. Palles

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: